Results 11 to 20 of about 1,181,836 (211)

Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis. [PDF]

Aliment Pharmacol Ther, 2021
Infliximab is a chimeric monoclonal antibody against tumour necrosis factor‐alpha for the treatment of Crohn's disease (CD) and ulcerative colitis (UC).
Hanzel J, Bukkems LH, Gecse KB, D'Haens GR, Mathôt RAA.   +4 more
europepmc   +6 more sources

Efficacy and Safety of CT-P13 as First- and Second-Line Treatment in Patients with Ankylosing Spondylitis. [PDF]

J Clin Med
Background/Objectives: CT-P13 is a biosimilar version of infliximab, a monoclonal antibody. In individuals with ankylosing spondylitis (AS), CT-P13 has been shown to be effective and to have a well-tolerated safety profile.
Uslu S, Gülle S, Sen G, Capar S, Senel S, Dalkılıc E, Akar S, Koca SS, Tufan A, Yazici A, Yilmaz S, Inanc N, Birlik M, Solmaz D, Cefle A, Goker B, Direskeneli H, Yolbas S, Steen Krogh N, Yilmaz N, Erten S, Bes C, Soysal Gündüz O, Oztürk MA, Haznedaroglu S, Yavuz S, Onen F, Sari I.   +27 more
europepmc   +7 more sources

CT-P13: design, development, and place in therapy [PDF]

Drug Design, Development and Therapy, 2017
Tommaso Gabbani,1 Simona Deiana,2 Vito Annese3 1Gastroenterology Unit, Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì, 2Division of Gastroenterology, AOU Careggi University Hospital, Florence, Italy; 3Gastroenterology Department, Valiant ...
Gabbani T, Deiana S, Annese V
doaj   +6 more sources

Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT‐P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study [PDF]

Clinical and Translational Science, 2022
Data regarding double switching from originator infliximab (IFX) to IFX biosimilars in inflammatory bowel diseases (IBDs) are lacking. The purpose of this study was to evaluate the safety and efficacy of switching from originator IFX to CT‐P13 and ...
Stefano Mazza, Nicole Piazza O. Sed, Francesco Simone Conforti, Alberto Fascì, Alessandro Rimondi, Beatrice Marinoni, Valentina Casini, Chiara Ricci, Francesca Munari, Lorena Pirola, Pietro Invernizzi, Carlo Girelli, Guido Lupinacci, Luca Pastorelli, Flaminia Cavallaro, Luca Ferraris, Alice Colucci, Arnaldo Amato, Gian Eugenio Tontini, Maurizio Vecchi, Gionata Fiorino, Flavio Caprioli   +21 more
doaj   +3 more sources

Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective [PDF]

PLoS ONE
BackgroundThe Saudi Food and Drug Authority (SFDA) has approved the subcutaneous (SC) administration of infliximab, presenting a more convenient alternative with reduced outpatient visits and diminished expenses compared to the intravenous (IV ...
Nimer S. Alkhatib, Abdulaali R. Almutairi, Majid Almadi, Shiraz Halloush, Yazed Sulaiman H. Al-Ruthia, Omar Rashdan, Samah Al-Shatnawi, Nahla A. Azzam, Mahmoud H. Mosli, Amal M. Badawoud, Majed S. Al Yami, Abdulaziz Alhossan, Ibtisam AlHarbi   +12 more
doaj   +4 more sources

Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study. [PDF]

J Crohns Colitis, 2022
Background Intravenous [IV] infliximab is a well-established therapy for inflammatory bowel diseases [IBD] patients. A subcutaneous [SC] formulation of infliximab [CT-P13] has recently been shown to be as effective as IV infliximab after two doses of IV ...
Smith PJ, Critchley L, Storey D, Gregg B, Stenson J, Kneebone A, Rimmer T, Burke S, Hussain S, Yi Teoh W, Vazeille S, Serna S, Steel A, Derbyshire E, Collins P, Dibb M, Flanagan P, Probert C, Verma AM, Subramanian S.   +19 more
europepmc   +2 more sources

Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies. [PDF]

Drug Saf, 2023
Biosimilar CT-P13 was approved with limited data from clinical trials compared to the originator infliximab in biologic-naïve patients with rheumatoid arthritis.
Takeuchi T, Nishikawa K, Yamada F, Morita A, Ohtsuki M, Suzuki Y, Watanabe M, Yamanaka H, Hibi T.   +8 more
europepmc   +2 more sources

A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn’s disease [PDF]

Therapeutic Advances in Drug Safety, 2022
Inflammatory bowel diseases (IBDs) are chronic immune disorders of unclear etiology. Tumor necrosis factor (TNF) inhibitors are effective for IBD treatment and are cost-effective because they reduce hospital admissions and are associated with fewer ...
Shin Kashima, Koji Sawada, Kentaro Moriichi, Mikihiro Fujiya   +3 more
doaj   +2 more sources

Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID‐19) pandemic: A case series [PDF]

Clinical Case Reports, 2022
The COVID‐19 pandemic highlighted the benefits of subcutaneous (SC) administration for healthcare systems. The first SC infliximab, CT‐P13 SC, was safe and effective for the treatment of psoriatic arthritis. Observed patient preferences for continuing CT‐
Xenofon Baraliakos, Styliani Tsiami, Sooraj Vijayan, Haewon Jung, Nick Barkham   +4 more
doaj   +2 more sources

Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies. [PDF]

Inflamm Bowel Dis
Background Superior efficacy of subcutaneous infliximab (CT-P13 SC) over placebo for maintenance therapy in patients with Crohn’s disease (CD) and ulcerative colitis (UC) was demonstrated in the randomized LIBERTY-CD and LIBERTY-UC studies.
Schreiber S, Colombel JF, Hanauer SB, Sandborn WJ, Danese S, Lee SJ, Kim SH, Bae YJ, Lee SH, Lee SG, Lee JH, Kim JM, Park GH, Lee J, Lee JH, Kim CY, Sands BE.   +16 more
europepmc   +2 more sources